Repository logo

2021 DORIS definition of remission in SLE: final recommendations from an international task force.

Published version

Change log


van Vollenhoven, Ronald F  ORCID logo
Bertsias, George 
Isenberg, David 


OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS). BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. METHODS: Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. RESULTS: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. CONCLUSION: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.



healthcare, lupus erythematosus, outcome assessment, systemic, therapeutics, Humans, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Prednisolone, Remission Induction, Severity of Illness Index

Journal Title

Lupus Sci Med

Conference Name

Journal ISSN


Volume Title



UCB Pharma (n/a)
GlaxoSmithKline (n/a)